BofA raised the firm’s price target on Alkermes (ALKS) to $31 from $28 and keeps a Neutral rating on the shares, citing a higher multiple given the recent move in biotech peer comps for the ...
Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug ...
Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...
Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported third-quarter profit of $92.4 million. On a per-share basis, the Dublin-based company said it had profit of 55 cents.